Peroneal Longus to Brevis Transfer Augmentation With TeKBrace Synthetic Graft.

Foot Ankle SpecApr 20, 2026 (epub)
Case ReportOrthopedic Surgery

Justin Daigre

✦ AI-curated · Sources linked

Case in brief

A 31-year-old man with persistent lateral ankle pain following an inversion injury was diagnosed with tears in both peroneal tendons. After conservative treatments failed, he underwent a peroneus longus to brevis tendon transfer augmented with a TeKBrace synthetic graft. Postoperatively, he experienced minimal muscle atrophy and a rapid return to activities, with no complications reported.

Diagnostic / clinical pearl

The use of synthetic graft augmentation in tendon transfer procedures may enhance recovery and functional outcomes in patients with complex peroneal tendon injuries.

Why it matters

This case suggests that synthetic grafts could be a valuable option in tendon transfers, particularly for patients with poor tissue quality, warranting further investigation in larger studies.

Source

PubMed · PMID 42007849

Published in Foot Ankle Spec. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.